Tokyo, Japan - November 17, 2023 - Medical ＆ Biological Laboratories Co., Ltd. (CEO: Hiroki Ito), a JSR Life Sciences Company, announced today that it will release an automated mono-test chemiluminescence immunoassay (CLIA) analyzer “iStar 500” worldwide.
The iStar is a highly automated mono-test analyzer based on CLIA technology. The compact and integrated design, combined with highly sensitive CLIA technology, makes it an ideal choice for emergency diagnosis or small- to medium-sized labs looking for accurate testing results.
The bench top CLIA analyzer offers a wide range of testing parameters including cardiac markers, reproductive health, liver health, tumor markers and autoimmunity.
For cardiac biomarkers, whole blood is an analyte for measuring the markers and allows healthcare professionals to make timely and informed decisions for patients. MBL is proud to offer excellent assay performance for whole blood type cardiac biomarkers in the world with Japan quality.
Head Quarter: SUMITOMO FUDOSAN SHIBADAIMON NICHOME BLDG. 2-11-8 Shibadaimon, Minato-ku, Tokyo 105-0012 Japan
Contact details
-
Download vCard
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
MEBGEN™ BRAF 2 Kit Receives MHLW Approval as a Companion Diagnostic for Use with Patients with Thyroid Cancer
With this approval, the MEBGEN™ BRAF 2 Kit is expected to contribute to the timely personalized treatment for patients with radically unresectable thyroid cancer based on the presence or absence of...
Notice of Approval for First-Class Marketing License for Medical Devices
With the acquisition of the First-Class Marketing License for Medical Devices, MBL will be able to market highly controlled medical devices, including genetic testing systems using NGS.
MEBGEN™ BRAF 3 Kit Receives MHLW Approval and Insurance Coverage as a Tumor Agnostic Companion Diagnostic
With MHLW approval and insurance coverage, the MEBGEN™ BRAF 3 Kit is expected to support personalized medicine based on its ability to detect the presence or absence of BRAF gene mutations in rare ...
New Antibody Development for Use in Drug Delivery to Motor Nerves
MBL raised and delivered monoclonal antibodies for Jiksak Bioengineering, a startup company with proprietary technologies developed for new therapeutic innovation in motor neuron degenerative disea...